Pharm to Table

LC Campeau, Dani Schultz
  • 0,0 (0)
  • Scheikunde

A podcast hosted by L.-C. Campeau and Dani Schultz that dives into the stories about the people behind the chemistry and science that happens at #MerckChemistry. Follow us on X (formerly Twitter) at @PharmToTablePod, @DrLCSquare, @danithechemist Email us comments and suggestions at pharmtotablepod@gmail.com

  1. SE5:E1 - A Journey of Synthetic Chemistry Innovations at Merck

    18 mei

    SE5:E1 - A Journey of Synthetic Chemistry Innovations at Merck

    To kick off Season 5, Dani and LC discuss a recent perspective published in the Journal of Organic Chemistry that highlights innovations in synthetic chemistry which trace their origins to the work of discovering, developing and commercializing novel therapeutics. This publication was the most accessed paper published in JOC in 2025! Dani and LC explore the motivations on writing it, its main thesis and lesson learned from reexamining nearly 75 years of chemistry innovations at Merck. Be sure to listen through to the very end for a special Season 5 theme reveal! Read and listen to some of the papers we discussed today: From Cortisone to Enlicitide: A Journey of Synthetic Chemistry Innovations at Merck Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠⁠⁠⁠⁠⁠⁠

    41 min.
  2. SE4:E8: From Discovery to Process, Part 2: Getting Ugi with it - scaling a 3CL protease inhibitor

    23 mrt

    SE4:E8: From Discovery to Process, Part 2: Getting Ugi with it - scaling a 3CL protease inhibitor

    In Part 2 of our Pharm to Table deep dive on MK‑7845, Dani and LC shift from invention to implementation, welcoming process chemists Nastaran Salehi Marzijarani and Ben Turnbull to the pod. We explore how the team re‑imagined the synthesis to enable robust, scalable supply—and why a classic multicomponent reaction you probably remember from school, the Joullié–Ugi reaction, ended up stealing the show. Along the way, we unpack route selection trade‑offs, lifecycle thinking in process chemistry, and what it really takes to bring an antiviral to life at scale. Read and listen to some of the papers we discussed today: Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19 - Org. Lett. Part 1 of MK-7845 series: SE4:E7: From Discovery to Process, Part 1: Building a 3CL Protease Inhibitor Through Smart Fluorine Placement and Design Intuition Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠⁠⁠⁠⁠⁠

    31 min.
  3. SE4:E7: From Discovery to Process, Part 1: Building a 3CL Protease Inhibitor Through Smart Fluorine Placement and Design Intuition

    2 feb

    SE4:E7: From Discovery to Process, Part 1: Building a 3CL Protease Inhibitor Through Smart Fluorine Placement and Design Intuition

    In this first installment of our two‑part Pharm to Table special on MK‑7845, Dani and LC sit down with medicinal chemist Valerie Shurtleff to unpack the discovery journey behind this 3CL protease inhibitor—from early structural insights to an unexpectedly effective difluorobutyl isostere. Val walks us through how the team balanced potency, VLE, metabolic challenges, and design intuition to land on a well‑rounded preclinical candidate - one of the most dynamic programs of her career. Along the way, she reminds us why asking good questions, collaborating relentlessly, and occasionally surviving a “Hot Ones” challenge are all essential scientific skills. It’s an episode packed with chemistry, creativity, and just enough fluorine to keep things spicy. Stay tuned for Part 2, where we shift from invention to implementation and explore how the process chemistry team brought MK‑7845 to life at scale. Read some of the papers we discussed today: Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic - J. Med. Chem. Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠⁠⁠⁠⁠

    29 min.
  4. SE4:E6 - Mechanism-Driven Innovation in Process Research: Yining Ji Chen’s Road as a Rising Star

    10-11-2025

    SE4:E6 - Mechanism-Driven Innovation in Process Research: Yining Ji Chen’s Road as a Rising Star

    Join us for a conversation with Yining Ji Chen, recipient of the 2025 ACS Rising Star Award, on how mechanistic insight powers innovation in pharmaceutical process research. We dive into her career journey and standout projects—from Pd-catalyzed C–N coupling for HCV therapy to dynamic phosphorylation in nucleotide synthesis—plus her creation of LED‑NMR for real-time photochemical reaction monitoring. Hear how deep mechanistic understanding drives robustness and safety, why she moved to the Data‑Rich Measurements group, and which emerging analytical technologies excite her most. A celebration of scientific rigor shaping efficient, reliable pharma processes! Read some of the papers we discussed today: A multifunctional catalyst that stereoselectively assembles prodrugs - Science A rational pre-catalyst design for bis-phosphine mono-oxide palladium catalyzed reactions - Chem Sci LED-Illuminated NMR Spectroscopy: A Practical Tool forMechanistic Studies of Photochemical Reactions - ChemPhotoChem From at-line to online NMR: coupling probe-based autosampler with benchtop NMR - Reaction Chemistry and Engineering Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠⁠⁠⁠

    31 min.
  5. SE4:E5 - Evolution of a Green Chemistry Trailblazer

    13-10-2025

    SE4:E5 - Evolution of a Green Chemistry Trailblazer

    In this episode, Dani and LC welcome Jeff Moore, recipient of the 2025 ACS Affordable Green Chemistry Award, to discuss his pioneering work in biocatalysis at Merck. The conversation explores the evolution (pun intended) of biocatalytic processes in pharmaceutical manufacturing, highlighting key milestones such as the adoption of transaminases and imine reductases, and their impact on drug synthesis and sustainability. Jeff shares stories from his career, including how being 'lazy' when doing science can lead to major innovations and the practical benefits of enzyme-driven chemistry. He even leaves us with insights into the future frontiers of biocatalysis, from cascade reactions to microfluidics. Read some of the papers we discussed today: Convergent Kilogram-Scale Synthesis of Dual Orexin Receptor Antagonist - Organic Letters Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture - Science Enabling Biocatalysis by High-Throughput Protein Engineering Using Droplet Microfluidics Coupled to Mass Spectrometry - ACS Omega Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠⁠⁠

    37 min.
  6. SE4:E4 - MedChem Masters: Molecules, Mentors and Mindsets

    19-08-2025

    SE4:E4 - MedChem Masters: Molecules, Mentors and Mindsets

    In this episode, Dani and LC interview Dr. Shane Krska, recipient of the ACS Arthur C. Cope Award, and Dr. Petr Vachal, recipient of the ACS Earle B. Barnes Award for Leadership in Chemical Research Management. Shane shares his pioneering work in catalytic methods and high-throughput experimentation (HTE) for drug discovery, while Petr discusses his leadership role driving innovation at Merck. They reflect on their career journeys from graduate school to industry, emphasizing personal growth and the importance on taking on diverse roles. We wrap it up by asking Shane and Petr what has made them the most proud over their 20+ year careers - which spans from innovations in direct-to-biology for accelerating design-make-test to advancing peptides as a modality of the future! Read the papers we discussed today: The Catalysis Laboratory at Merck: 20 Years of CatalyzingInnovation The medicinal chemist's toolbox for late stage functionalization of drug-like molecules Highly Efficient Asymmetric Synthesis of Sitagliptin Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠⁠

    36 min.
  7. S4:E3 - London Calling ... Spirocycles

    19-05-2025

    S4:E3 - London Calling ... Spirocycles

    This month we sit down with Damien Valette, Olivia Boyd and David Petrone to chat about their latest paper in Organic Letters on the desymmetrization of prochiral dienones to control all-carbon quaternary centers. This reaction leverages biocatalysis, specifically an ene-reductase [ERED] enzymes (which are making their second appearance on the pod - see S1:E5). David, Damien and Olivia walk us through the discovery of the reaction and why it's uniquely suited to set these challenging stereocenters. This work was done in the context of work at the med-chem/process interface which we explore as well. Damien and Olivia hail from our London UK MSD site and give us details on the progress of our company's build in the region as well as chat with us about how to be successful when collaborating with scientists on another continent (David). Read the papers we discussed today: HTE-Enabled Development of an Ene-Reductase-Catalyzed Desymmetrization: Remote Control of All-Carbon Quaternary γ-Centers ⁠- Org Lett 2024 Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table⁠

    34 min.
  8. S4:E2 - Making Sulfur Smell like Success!

    21-04-2025

    S4:E2 - Making Sulfur Smell like Success!

    Join us on the Pharm to Table podcast for a delightful chat with Ethan Wappes from our South San Francisco site, as we dive into the exciting world of thiophene synthesis! Ethan is a member of our Discovery Process Chemistry group and worked alongside medicinal chemists to devise a better synthetic route towards substituted thiophenes. Ethan shares insights from his recent Org. Lett. on a novel Rh-catalyzed [3+2] method that opens the door to highly substituted dihydrothiophenes, enhancing our medicinal chemistry toolkit. We explore how this strategy not only simplifies complex thiophene syntheses but also paves the way for new drug development possibilities! Read the papers we discussed today: Fully Substituted Thiophene Synthesis via (3 + 2) with Thiadiazoles - Org Lett 2024 Follow the Pharm to Table podcast on X - ⁠⁠⁠⁠@PharmtoTablePod ⁠⁠⁠⁠Visit our website at ⁠⁠⁠⁠https://podcasters.spotify.com/pod/show/pharm-to-table

    27 min.
Bekijk alles (53)

Trailer

Info

A podcast hosted by L.-C. Campeau and Dani Schultz that dives into the stories about the people behind the chemistry and science that happens at #MerckChemistry. Follow us on X (formerly Twitter) at @PharmToTablePod, @DrLCSquare, @danithechemist Email us comments and suggestions at pharmtotablepod@gmail.com

Informatie

  • Maker
    LC Campeau, Dani Schultz
  • Jaren actief
    2021 - 2026
  • Afleveringen
    53
  • Beoordeling
    Veilig
  • Copyright
    © LC Campeau, Dani Schultz
  • Website van aflevering
    Pharm to Table

Suggesties voor jou